07:00 , Jun 13, 2016 |  BC Week In Review  |  Company News

Takeda, Roivant Sciences deal

Takeda and Roivant launched Myovant Sciences Ltd. Takeda granted the newco exclusive, worldwide rights outside of Japan and other Asian countries to relugolix ( TAK-385 ) and worldwide rights to RVT-602 ( TAK-448 ). Relugolix...
07:00 , Apr 16, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: KISS1 receptor (KISS1R; GPR54); KISS-1 metastasis suppressor (KISS1; kisspeptin)

Endocrine/metabolic disease INDICATION: Hypogonadism In vitro and sheep studies suggest a kisspeptin-based lipopeptide could help treat hypogonadotropic hypogonadism caused by low levels of luteinizing hormone. The lipopeptide consisted of an endogenous kisspeptin peptide modified with...
07:00 , Sep 18, 2008 |  BC Innovations  |  Distillery Therapeutics

This Week in Therapeutics

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Infertility; obesity CREB-regulated transcription coactivator 1 (CRTC1; TORC1); CART prepropeptide (CARTPT); KiSS-1 metastasis-suppressor (KISS1) Studies in cell culture and in...
07:00 , Jun 4, 2001 |  BC Week In Review  |  Company News

Takeda Chemical other research news

Takeda published in Nature the identification and function of the protein associated with the KiSS-1 metastasis suppressor gene. The gene product is a 54 amino acid peptide called metastin that is amidated on the carboxy-terminus...